Crystagen

Crystagen is a synthetic tripeptide (Glu-Asp-Pro) from the Khavinson bioregulator family, researched for thymic-tissue-targeted bioregulation, immune system function, and T-cell-derived cellular activity. It is one of the synthesized Khavinson compounds with a defined three-amino-acid sequence and overlaps in functional positioning with Thymalin (the polypeptide thymic extract). Crystagen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Crystagen and how does the thymic bioregulatory mechanism work?

Crystagen is a synthetic Glu-Asp-Pro tripeptide proposed to enter thymic-tissue cell nuclei and modulate gene expression in pathways related to T-cell maturation, immune regulation, and thymic function. For the framework behind that proposal, see the science of Khavinson bioregulators. Within the Khavinson framework, Crystagen is the synthesized single-sequence complement to Thymalin (the polypeptide thymic extract), with both targeting immune function but through different molecular forms — Crystagen as a defined tripeptide, Thymalin as a multi-component extract. Preclinical work has reported effects on T-cell function markers and immune regulation parameters.

Evidence level: preclinical (cell culture, rodent); Khavinson-group research; independent replication limited

What does the research show for Crystagen?

A thymic/immune target is Crystagen's designation within the Khavinson framework; the verifiable preclinical record is in-vitro/cell-culture work on immune-cell and thymocyte parameters (e.g., peptidergic regulation of thymocyte differentiation during thymus aging), rather than robust rodent-efficacy or independently replicated data. No Crystagen-specific human clinical trial has been published. The human clinical track record in this space belongs to Thymalin — the polypeptide thymic extract registered and used in Russia — not to the synthetic Crystagen tripeptide; the verifiable Crystagen record is limited to in-vitro/cell-culture work on immune-cell and thymocyte parameters. FDA-grade Phase 2/3 standards have not been applied.

Evidence level: Preclinical; Khavinson-group research; FDA-grade Phase 2/3 not conducted

How does Crystagen compare to other Khavinson peptide bioregulators targeting immunity?

Crystagen sits in the immune-targeting subset alongside Thymalin (polypeptide extract) and Vilon (dipeptide), with the three compounds proposed to act on overlapping but distinct aspects of immune function.

What are the documented side effects of Crystagen?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards.

Evidence level: preclinical safety; human long-term unestablished

What is the regulatory status of Crystagen?

Crystagen is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Crystagen is not on the FDA's active Section 503A/503B Category-2 bulk-substances list and was not among the peptides addressed in the FDA's April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting — no U.S. compounding pathway applies to it. Regulatory context in FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Crystagen vendor verification matter?

Crystagen's short tripeptide structure (Glu-Asp-Pro) makes synthesis straightforward, but identity verification requires mass spectrometry confirmation to distinguish from related Khavinson tripeptides and ensure correct sequence. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

How does Peptigrity verify Crystagen vendors?

Peptigrity collects independent third-party Certificates of Analysis for Crystagen from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does Crystagen do?

Crystagen is proposed to act on thymic and T-cell function through epigenetic gene-expression modulation, with preclinical research focused on immune regulation markers. Human Phase 2/3 efficacy is not established at Western clinical standards.

How does Crystagen differ from Thymalin?

Crystagen is a synthesized single-sequence tripeptide (Glu-Asp-Pro); Thymalin is a polypeptide extract from bovine thymus tissue containing multiple constituent peptides. Crystagen is more standardizable and easier to characterize; Thymalin has the Russian clinical-practice approval and longer human-use track record.

Is Crystagen legal to purchase?

Crystagen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Crystagen be FDA-approved?

No active FDA approval pathway exists for Crystagen as of August 2026.

How can I verify a Crystagen vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Crystagen dose?

No. Crystagen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Crystagen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.